Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 10 hours ago

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's.

Business Wire • Feb 17, 2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today reported the grant during December 2025, January 2026, and February 2026 of an aggregate of 153,218 restricted stock units (RSUs) and 34,952 stock options of the company's common stock to 36 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under.

Business Wire • Feb 13, 2026

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2025. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2025 financial results is completed a.

Business Wire • Jan 9, 2026

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materially decreased our position as we evaluate this specific risk.

Seeking Alpha • Dec 15, 2025

Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript

Evolus, Inc. ( EOLS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nareg Sagherian - Head of Global Investor Relations & Corporate Communications David Moatazedi - President, CEO & Director Rui Avelar - Chief Medical Officer and Head of Research & Development Tatjana Mitchell - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Sam Eiber - BTIG, LLC, Research Division Presentation Operator Good afternoon, everyone, and thank you for standing by.

Seeking Alpha • Nov 8, 2025

Evolus Reports Third Quarter 2025 Financial Results

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2025. “Our third quarter results reflect double-digit growth despite the current market environment. Our continued above market performance and disciplined expense management, create an important transition point for the company, as we continue to expec.

Business Wire • Nov 5, 2025

Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.

Zacks Investment Research • Nov 6, 2025

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 29, 2025

Evolus to Participate in 2025 Stifel Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Stifel Healthcare Conference. The fireside chat will take place on Tuesday, November 11, 2025, at 11:20 AM ET. The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay.

Business Wire • Oct 28, 2025